Satellos Bioscience Inc. Common Stock (MSLE)

FairStock Score: 22/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

At the close on 2026-10-13, Satellos traded at $7.04 with a market cap of $151.7 million. This is a clinical-stage biotechnology company with 18 employees, no meaningful revenue, and a lead oral drug candidate, SAT-3247, for Duchenne muscular dystrophy. Its proprietary MyoReGenX platform is interesting, but I do not confuse a scientific platform with a durable competitive moat. A moat exists only after a product is approved, protected, and profitably sold. Today, there is no such evidence. The financials are speculative: FairStock calculates a negative P/E of -3.40 and a P/B of 2.44, while trailing twelve-month free cash flow was -$29.0 million, a -19.1% FCF yield. Return on equity was -70.45% and return on capital employed was -41.89%. The Piotroski F-Score is 1/9, which is very weak. The Altman Z-Score of 14.42 suggests low balance-sheet distress by that formula, but for a no-debt clinical-stage company, that metric offers limited comfort. There is no Lynch category because only 0 years of filed results are available, so there is no record to judge growth. The 52-week range of $5.30 to $13.40 shows how sentiment can swing. Valuation rests almost entirely on future trial outcomes, not current earnings or cash flow. As Graham would say, this is not an investment in a proven business; it is a wager on binary scientific events. I would demand a much larger margin of safety before paying 2.44 times book for a company burning cash with no revenue.

In plain English: Satellos is a small drug company trying to develop a medicine for Duchenne muscular dystrophy. The business looks weak today because it has no profits, spends cash, and its financial scores are poor. The price looks expensive against what the company currently earns, so it depends heavily on future drug trials succeeding.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer